Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Ando M, Eguchi K, Shinkai T, Tamura T, Ohe Y, Yamamoto N, Kurata T, Kasai T, Ohmatsu H, Kubota K, Sekine I, Hojo N, Matsumoto T, Kodama T, Kakinuma R, Nishiwaki Y, Saijo N.
Ando M, et al. Among authors: kurata t.
Br J Cancer. 1997;76(11):1494-9. doi: 10.1038/bjc.1997.584.
Br J Cancer. 1997.
PMID: 9400948
Free PMC article.
Clinical Trial.